Inhibitor of apoptosis proteins as therapeutic targets in bladder cancer

Philipp Wolf

doi:10.3389/fonc.2023.1124600

Inhibitor of apoptosis proteins as therapeutic targets in bladder cancer

Front Oncol. 2023 Feb 10:13:1124600. doi: 10.3389/fonc.2023.1124600. eCollection 2023.

Author

Philipp Wolf^{1

2}

Affiliations

¹ Department of Urology, Medical Center-University of Freiburg, Freiburg, Germany.
² Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Abstract

Evasion from apoptosis is a hallmark of cancer. Inhibitor of apoptosis proteins (IAPs) contribute to this hallmark by suppressing the induction of cell death. IAPs were found to be overexpressed in cancerous tissues and to contribute to therapeutic resistance. The present review focuses on the IAP members cIAP1, cIAP2, XIAP, Survivin and Livin and their importance as potential therapeutic targets in bladder cancer.

Keywords: Livin; Survivin; XIAP; apoptosis; bladder cancer; cIAP1; cIAP2; inhibitor of apoptosis proteins.

Publication types

Review

Grants and funding

We acknowledge support by the Open Access Publication Fund of the University of Freiburg.